Full Text View
Tabular View
No Study Results Posted
Related Studies
The Role of Calcipotriol as Radioprotector of Skin
This study is not yet open for participant recruitment.
Verified by Rabin Medical Center, January 2007
First Received: March 7, 2007   No Changes Posted
Sponsored by: Rabin Medical Center
Information provided by: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT00445250
  Purpose

Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast. To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.


Condition Intervention Phase
Radiodermatitis
Drug: Calcipotriol
Phase II

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Radiation Therapy
Drug Information available for: Calcipotriene
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.

Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • Prevention of radiodermatitis

Secondary Outcome Measures:
  • Side effects of Calcipotriol

Estimated Enrollment: 50
Detailed Description:

STUDY PROTOCOL Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:

  1. . an assessment by a physician and a nurse according to the RTOG score (6).

    As follows:

    Grade 0 – no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 – extensive moist peeling, pitting edema. Grade 4 – ulcers, bleeding and necrosis.

  2. . A questionnaire to each patient regarding the efficacy and safety of the cream.
  3. . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment.

Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.

The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.

INCLUSION CRITERIA

  1. . Age ranging from 18 to 75.
  2. . Confirmed histological diagnosis of Breast cancer.
  3. . Radiotherapy treatment to the breast following lumpectomy.

EXCLUSION CRITERIA

  1. . Scleroderma.
  2. . An extremely large breast. Interfiled above 25 cm.
  3. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. . Mastectomy.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ranging from 18 to 75.
  2. Confirmed histological diagnosis of Breast cancer.
  3. Radiotherapy treatment to the breast following lumpectomy.

Exclusion Criteria:

  1. Scleroderma.
  2. An extremely large breast. Interfiled above 25 cm.
  3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
  4. Mastectomy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00445250

Contacts
Contact: Eyal Fenig, M.D. 97239377964 efenig@clalit.org.il
Contact: Ofer Purim, M.D. 97239377973 oferp@clalit.org.il

Locations
Israel
Rabin Medical Center
Petach Tiqva, Israel, 49100
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Eyal Fenig, M.D. Rabin Medical Center
  More Information

No publications provided

Study ID Numbers: 004253
Study First Received: March 7, 2007
Last Updated: March 7, 2007
ClinicalTrials.gov Identifier: NCT00445250     History of Changes
Health Authority: Israel: Ministry of Health

Keywords provided by Rabin Medical Center:
Calcipotriol
Breast
Cancer
Radiotherapy
Radiodermatitis in Breast Cancer

Study placed in the following topic categories:
Calcipotriene
Skin Diseases
Wounds and Injuries
Disorders of Environmental Origin
Radiodermatitis
Breast Neoplasms
Radiation Injuries
Dermatitis

Additional relevant MeSH terms:
Calcipotriene
Skin Diseases
Therapeutic Uses
Wounds and Injuries
Disorders of Environmental Origin
Radiodermatitis
Dermatologic Agents
Pharmacologic Actions
Radiation Injuries
Dermatitis

ClinicalTrials.gov processed this record on May 06, 2009